NanoCellect Biomedical
San Diego-based NanoCellect Biomedical innovates in cell analysis and sorting biotechnology.
Founded
2009San Diego-based NanoCellect Biomedical innovates in cell analysis and sorting biotechnology.
Founded in San Diego, NanoCellect Biomedical is a biotech company dedicated to advancing cell analysis and sorting technologies. Their core mission is to provide innovative, accessible solutions for researchers working with stem cells and fragile cells. The company's flagship product, the WOLF G2 Cell Sorter, offers gentle microfluidic sorting, ensuring the health and integrity of delicate cell types. NanoCellect's technology supports applications such as iPSC clonal outgrowth and CRISPR/Cas9 gene editing, catering to the needs of the biomedical research community.
Notable figures affiliated with NanoCellect include experienced biotech professionals and scientists who contribute to its innovative edge. The company has secured investments from prominent venture capital firms, underscoring its potential and industry relevance. Key achievements include the successful commercialization of the WOLF G2 Cell Sorter and its adoption by leading research institutions. NanoCellect's impact is evident in its contribution to advancing cell biology research, particularly in maintaining the viability and functionality of sensitive cell populations.
Companies similar to NanoCellect Biomedical include CytoRecovery, CytoMag, Cell Microsystems and Nodexus.
NanoCellect Biomedical was founded in 2009.
NanoCellect Biomedical's headquarters is located in San Diego, CA, US.
NanoCellect Biomedical's most recent funding round was for $20M (USD) in August 2021.
As of Aug 13, 2021, NanoCellect Biomedical has disclosed funding of $47M (USD). Undisclosed round amounts are excluded.
NanoCellect Biomedical has 85 employees as of Feb 5, 2024.
nodexus.com
